Daniel Brennan, an analyst from TD Cowen, maintained the Buy rating on Revvity (RVTY – Research Report). The associated price target was raised to $126.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Daniel Brennan’s rating is based on Revvity’s ability to deliver solid first-quarter results despite a challenging market environment. The company maintained its organic growth and earnings per share guidance for fiscal year 2025, demonstrating resilience against significant cost pressures, particularly from tariffs. Revvity’s strength in non-US academic sectors, such as software and diagnostics, helped offset weaker performance in instruments, showcasing the company’s strategic portfolio positioning.
Moreover, management’s confidence in mitigating tariff-related challenges and the robust growth in the software segment, which exceeded 20% year-over-year, further supports the positive outlook. The diagnostics segment also performed well, with notable growth in ImmunoDx and reproductive health. These factors collectively contribute to Daniel Brennan’s Buy rating for Revvity, reflecting favorable trends and effective execution in the company’s non-instrument businesses.
In another report released today, Citi also maintained a Buy rating on the stock with a $135.00 price target.